STOCK TITAN

Fortune 100 tie-up: IB Acquisition (NASDAQ: IBAC) and GNQ partner on AI drug discovery

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
425

Rhea-AI Filing Summary

IB Acquisition Corp. reported that GNQ Insilico Inc. entered a Joint Initiative Agreement and Joint Marketing Attachment with a Fortune 100 global technology company on March 13, 2026 to collaborate on sales, marketing, development and alliance activities advancing AI-driven drug discovery and precision medicine solutions.

The collaboration has a global territory, an initial term of two years and is non-exclusive. The parties will jointly market combined solutions that integrate GNQ’s AI platforms with the Strategic Partner’s consulting, cloud, and quantum computing capabilities. This Form 8-K also states that IB Acquisition intends to file a Form S-4 registration statement and a proxy statement/prospectus in connection with the proposed business combination with GNQ.

Positive

  • None.

Negative

  • None.

Insights

Transaction disclosure and regulatory steps are underway; shareholder approval and SEC filings are central next steps.

The filing confirms intent to combine IBAC and GNQ and states IBAC will file a Form S-4 and send a proxy statement/prospectus to stockholders. The proxy and registration process triggers regulatory review and stockholder votes as standard closing conditions.

Key dependencies include the approval by the stockholders, satisfaction of minimum trust account amounts, and SEC review. Subsequent SEC filings will show definitive terms, financing status, and closing conditions.

Partnership targets combined go‑to‑market for AI drug discovery using GNQ platforms plus cloud and quantum capabilities.

The Agreement frames a joint marketing and development effort with a global territory and an initial two‑year term, labeled non-exclusive. It describes joint business planning, lead identification, and delivering integrated solutions across healthcare and life sciences.

Operational impact will depend on executed joint business plans and customer adoption; partner contributions listed include consulting, cloud, and quantum computing capabilities. Subsequent disclosures should detail specific product integrations, commercial milestones, and revenue arrangements.

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): March 13, 2026

 

IB ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

 

Nevada   001-41988   85-2946784
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (I.R.S. Employer
Identification Number)

 

1200 N Federal Highway, Suite 215

Boca Raton, FL 33432

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (214) 687-0020

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value US$0.0001 per share   IBAC   The Nasdaq Stock Market LLC
Rights, each entitling the holder to receive one-twentieth of one share of common stock   IBACR   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01. Other Events

 

Joint Initiative Agreement and Joint Marketing Attachment

 

On March 13, 2026, GNQ Insilico Inc. (“GNQ”) entered into a Joint Initiative Agreement and Joint Marketing Attachment (together, the “Agreement”) with a Fortune 100 global technology company (the “Strategic Partner”) to collaborate on sales, marketing, development, and other alliance project activities aimed at advancing AI-driven drug discovery and precision medicine solutions.

 

Under the terms of the Agreement, GNQ and the Strategic Partner will jointly market combined solutions that integrate GNQ’s proprietary AI-powered platforms with the Strategic Partner’s consulting, cloud, and quantum computing capabilities. The collaboration has a global territory and an initial term of two years, with the option to extend by mutual written agreement. The Agreement establishes a non-exclusive framework under which the parties will develop joint business plans, identify and pursue qualified customer leads, and deliver combined solutions to customers across the healthcare and life sciences ecosystem.

 

Important Information and Where to Find It

 

This Current Report on Form 8-K relates to a proposed transaction between IB Acquisition and GNQ. This Current Report on Form 8-K does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the transaction described herein, IB Acquisition intends to file relevant materials with the United States Securities and Exchange Commission (“SEC”), including a registration statement on Form S-4, which will include a document that serves as a joint prospectus and proxy statement, referred to as a proxy statement/prospectus. A proxy statement/prospectus will be sent to all IB Acquisition stockholders. IB Acquisition will also file other documents regarding the proposed transaction with the SEC. Before making any voting or investment decision, investors and security holders of IB Acquisition are urged to read the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction.

 

Investors and security holders will be able to obtain free copies of the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by IB Acquisition through the website maintained by the SEC at www.sec.gov.

 

The documents filed by IB Acquisition with the SEC also may be obtained free of charge upon written request to IB Acquisition Corp., 1200 N Federal Highway, Suite 215, Boca Raton, FL 33432 or via email at ecm@ibsgroup.net.

 

Participants in the Solicitation

 

IB Acquisition, GNQ and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from IB Acquisition’s stockholders in connection with the proposed transaction. A list of the names of such directors and executive officers, and information regarding their interests in the business combination and their ownership of IB Acquisition’s securities are, or will be, contained in IB Acquisition’s filings with the SEC. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the proxy statement/prospectus regarding the proposed transaction when it becomes available. You may obtain free copies of these documents as described in the preceding paragraph.

 

Non-Solicitation

 

This Current Report on Form 8-K is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of IB Acquisition, or GNQ, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the proposed Transaction between IBAC and GNQ. Such forward-looking statements include, but are not limited to, statements regarding the closing of the Transaction and IBAC’s, GNQ’s, or their respective management teams’ expectations, hopes, beliefs, intentions or strategies regarding the future. The words “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intends”, “may”, “might”, “plan”, “possible”, “potential”, “predict”, “project”, “should”, “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to assumptions, risks and uncertainties. These statements are based on various assumptions, whether or not identified in this Current Report on Form 8-K. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of IBAC and GNQ. Many factors could cause actual future events to differ from the forward-looking statements in this Current Report on Form 8-K, including but not limited to, (i) the risk that the Transaction may not be completed in a timely manner or at all, (ii) the failure to satisfy the conditions to the consummation of the Transaction, including the approval by the stockholders of IBAC, the satisfaction of the minimum trust account amount following any redemptions by IBAC’s public stockholders and the receipt of certain governmental and regulatory approvals, (iii) risks related to the timing, outcome and scope of review by the SEC of the registration statement on Form S-4, (iv) the inability to complete the Bridge Financing or PIPE offering, (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement, (vi) the outcome of any legal proceedings that may be instituted against IBAC and/or GNQ related to the business combination agreement, (vii) the ability to maintain the listing of IBAC’s stock on Nasdaq (or, if applicable, to list and maintain the listing of the combined entity on the NYSE), (viii) volatility in the price of IBAC’s securities, (ix) costs related to the Transaction and the failure to realize anticipated benefits of the Transaction, (x) the effect of the announcement or pendency of the Transaction on GNQ’s business relationships, operating results, performance and business generally, (xi) risks that the Transaction disrupts current plans and operations of GNQ, (xii) changes in the combined capital structure of IBAC and GNQ following the Transaction, (xiii) changes in the competitive industries and markets in which GNQ operates, (xiv) changes in laws and regulations affecting GNQ’s business, (xv) the ability to implement business plans and identify and realize additional opportunities, (xvi) risks related to GNQ’s projected financial information and limited operating history, (xvii) risks related to GNQ’s potential inability to achieve or maintain profitability and generate cash, (xviii) the enforceability of GNQ’s intellectual property, including its patents and the potential infringement on the intellectual property rights of others, and (xix) other risks and uncertainties indicated from time to time in the filings of IBAC, including the Form S-4 Registration Statement that IBAC will file. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IBAC and GNQ assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither IBAC nor GNQ gives any assurance that either IBAC or GNQ will achieve its expectations.

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IB ACQUISITION CORP.
   
  By: /s/ Al Lopez
  Name: Al Lopez
  Title: Chief Executive Officer

 

Dated: March 18, 2026

 

2

 

 

FAQ

What did IBAC disclose about the GNQ partnership?

IBAC disclosed that GNQ entered a Joint Initiative Agreement with a Fortune 100 technology company on March 13, 2026, to jointly market and develop AI-driven drug discovery and precision medicine solutions globally under a two-year, non-exclusive framework.

Does the 8-K state how long the GNQ strategic agreement lasts?

Yes. The Agreement has an initial term of two years and may be extended by mutual written agreement, and it covers a global territory for joint sales, marketing, development and alliance activities.

Will IBAC seek shareholder approval for a transaction with GNQ?

Yes. The 8-K states IBAC intends to file a Form S-4 and a proxy statement/prospectus and that the transaction will require the approval by the stockholders of IBAC as a condition to closing.

What filings will IBAC make about the proposed business combination?

IBAC intends to file a registration statement on Form S-4 that will include a document serving as a joint proxy statement and prospectus; that proxy statement/prospectus will be sent to all IBAC stockholders.

Does the 8-K describe the Strategic Partner’s contributions?

Yes. The filing states the Strategic Partner will contribute consulting, cloud, and quantum computing capabilities to integrate with GNQ’s proprietary AI-powered platforms for combined customer solutions.
Ib Acquisition Corp

NASDAQ:IBAC

View IBAC Stock Overview

IBAC Rankings

IBAC Latest News

IBAC Latest SEC Filings

IBAC Stock Data

61.65M
1.52M
Shell Companies
Blank Checks
United States
BOCA RATON